Most Recent Articles by David Vaczek
Sandoz will need to put across the biosimilar concept to doctors as it challenges Neupogen and Teva's Granix
The biotech exec speaks about the global launch of his firm's lead product, Duchenne drug Translarna.
Novartis's Sandoz will kickstart its marketing plans as it awaits FDA's decision to approve the first biosimilar in the US.
Sandoz received FDA biosimilar nod; new technique yields 25 antibiotics; Novartis sends two COPD drugs for FDA review.
Siren, one of the most experienced agencies in the rare-disease space, will add its patient-outreach expertise to new owner Dohmen's patient-care model.